Off-Label Drug Use Needs Strong...( Stanford researcher chides FDA for pr...),Health

Stanford researcher chides FDA for proposing less governance of the practice

WEDNESDAY, April 2 (HealthDay News) -- U.S. Food and Drug Administration draft guidelines for oversight of off-label drug use would allow pharmaceutical companies to market more drugs for unapproved uses, one expert contends.

The proposed guidelines are a step in the wrong direction, Dr. Randall Stafford, an associate professor of medicine at the Stanford Prevention Research Center, wrote in an editorial published in the April 3 issue of the New England Journal of Medicine.

While the FDA approves drugs for specific purposes, doctors can use drugs off-label to treat other medical conditions that aren't included in the FDA approval. This is common practice, but what's known about the use of a drug for one condition may not apply to other situations, said Stafford, a Stanford University School of Medicine researcher. The use of antipsychotics for dementia and the use of antidepressants in children are key examples, he noted.

Stafford doesn't believe the FDA should start telling physicians how to practice, however. He said that physician judgment in such cases is critical, and off-label use of drugs can be helpful in certain cases where patients don't respond to approved therapies.

"But in other cases, off-label prescribing has become first-line therapy even in the absence of strong evidence of benefits and safety. This is problematic," Stafford said.

Such cases point to the need for a better method of evaluating and regulating off-label drug use, Stafford added. Ideally, a drug company would have to conduct additional studies and apply to the FDA for supplemental approval for a new clinical use of drug.

Currently, drug makers can't overtly promote drugs for off-label use but can give doctors educational materials about off-label use of a drug, most often in the form of published journal articles. This pr
'/>"/>